Immix Biopharma Announces Pricing of $125 Million Underwritten Offering of Common Stock

LOS ANGELES, Sept. 29, 2026 (GLOBE NEWSWIRE) — Immix Biopharma, Inc. (“ImmixBio”, “Company”, “we” or “us” or “IMMX”), a global leader in relapsed/refractory AL Amyloidosis, today announced the pricing of an underwritten registered offering of 11,363,637 shares of its common stock at a public offering price of $11.00 per share….
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks